Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/ANE.0000000000007233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sugammadex versus Neostigmine in Renal Impairment.
Anesth Analg
December 2024
Concord Repatriation General Hospital, Concord, New South Wales, Australia,
Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study.
Anesth Analg
January 2025
From the Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Background: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing.
View Article and Find Full Text PDFNeuromuscular Blockade Reversal with Sugammadex Reduces Cardiac Complications and OR Time for Prone Lumbar Spinal Fusion Compared to Neostigmine.
Spine (Phila Pa 1976)
December 2024
Brown University Department of Orthopaedic Surgery, Providence, Rhode Island.
Study Design: Retrospective cohort study.
Objective: To evaluate inpatient complication profiles of patients receiving neuromuscular blockade reversal via sugammadex versus neostigmine/glycopyrrolate.
Summary Of Background Data: Sugammadex is a neuromuscular blockade reversal agent that binds non-depolarizing muscle relaxants.
Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study.
Anesth Analg
October 2024
Department of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas.
Article Synopsis
- Neuromuscular blocking agents (NMBAs) are crucial in anesthesia for procedures like intubation and mechanical ventilation, but they carry risks of acute complications, especially in patients with chronic kidney disease (CKD).
- A study used a large health database to compare the outcomes of two NMBAs - rocuronium with sugammadex and cisatracurium with neostigmine - in CKD patients, focusing on various complications within a week and mortality up to 30 days post-administration.
- The results showed that patients receiving rocuronium with sugammadex had significantly higher risks of respiratory failure, acute respiratory distress, hypertensive crisis, heart failure, pleural effusion, and a greater
Effect of Neuromuscular Blockade Reversal on Postoperative Gastrointestinal Motility after Laparoscopic Cholecystectomy: Neostigmine / Atropine versus Sugammadex.
J Coll Physicians Surg Pak
October 2024
Private Hospital, Dubai, UAE.
Objective: To compare sugammadex with neostigmine / atropine combination for reversal of neuromuscular blocker agents in terms of postoperative gastrointestinal motility in patients who underwent laparoscopic cholecystectomy.
Study Design: Experimental study. Place and Duration of the Study: University of Health Sciences, Izmir Bozyaka Training and Research Hospital, Izmir, Turkiye, between December 2020 and June 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!